申请人:DANA-FARBER CANCER INSTITUTE, INC.
公开号:US20210361774A1
公开(公告)日:2021-11-25
Disclosed are bifunctional compounds (degraders) that target LRKK
2
for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the degraders to treat neurodegenerative diseases and disorders such as Parkinson's disease and brain cancer (e.g., gliomas and glioblastomas).